Perspectives in corticosteroid research
- PMID: 3076128
- DOI: 10.2165/00003495-198800365-00003
Perspectives in corticosteroid research
Abstract
In dermatotherapy, potent drugs are needed which can be used as alternatives to corticosteroids, but which are without unwanted local and systemic effects. Three theoretical possibilities for the development of such advanced drugs have been presented. Firstly, dissociation of wanted and unwanted effects by selection of a certain corticosteroid structure is proposed. However, this is impossible, because corticosteroid receptors are ubiquitous and all display the same specificity. Secondly, manipulation of the pathways of the inflammatory response may be more feasible. Because of increasing knowledge of the mechanism of inflammation and the pathogenesis of cutaneous inflammatory diseases, it is predictable that effective nonsteroidal anti-inflammatory drugs for topical use will be developed some time in the future. Lastly, the effects and side effects can now be limited to the site of application, thus avoiding systemic risks, by optimising corticosteroid activity with respect to receptor binding and pharmacokinetic properties. However, it is realistic to assume that, even in the future, corticosteroids will always possess both desirable and undesirable properties.
Similar articles
-
Topical corticosteroids. Which drug and when?Drugs. 1992 Jul;44(1):65-71. doi: 10.2165/00003495-199244010-00006. Drugs. 1992. PMID: 1379911 Review.
-
The safe use of topical corticosteroids in children.Pediatr Ann. 2001 Apr;30(4):225-9. doi: 10.3928/0090-4481-20010401-12. Pediatr Ann. 2001. PMID: 11303439 Review. No abstract available.
-
[Prescription and surveillance of steroidal and non-steroidal anti-inflammatory agents. Prescription and surveillance of a dermocorticoid treatment].Ann Dermatol Venereol. 2002 Oct;129(10 Suppl):S157-61. Ann Dermatol Venereol. 2002. PMID: 12718145 French. No abstract available.
-
Clinical potential of topical corticosteroids.Drugs. 1988;36 Suppl 5:38-42. doi: 10.2165/00003495-198800365-00008. Drugs. 1988. PMID: 3076130 Review.
-
[Corticosteroid therapy from the dermatologists' viewpoint].Z Allgemeinmed. 1971 Jun 20;47(17):903-5. Z Allgemeinmed. 1971. PMID: 5580990 German. No abstract available.
Cited by
-
Topical corticosteroids. Which drug and when?Drugs. 1992 Jul;44(1):65-71. doi: 10.2165/00003495-199244010-00006. Drugs. 1992. PMID: 1379911 Review.
-
Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris.Eur J Clin Pharmacol. 1990;39(4):349-51. doi: 10.1007/BF00315408. Eur J Clin Pharmacol. 1990. PMID: 2076716 Clinical Trial.
-
0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.Eur J Clin Pharmacol. 1992;42(2):159-61. doi: 10.1007/BF00278477. Eur J Clin Pharmacol. 1992. PMID: 1618247 Clinical Trial.
-
BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.Mol Vis. 2009 Dec 8;15:2606-16. Mol Vis. 2009. PMID: 20011631 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical